- $800.51m
- $483.19m
- $9.04m
Annual cashflow statement for Immunome, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.8 | -24.7 | -36.9 | -107 | -293 |
| Depreciation | |||||
| Non-Cash Items | 6.16 | 2.95 | 5.54 | 86.8 | 166 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.21 | 2.78 | 2.24 | 12 | 14.9 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -12.1 | -18.2 | -28.7 | -7.57 | -111 |
| Capital Expenditures | -0.586 | -0.079 | -0.248 | -0.831 | -53.5 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | — | -29.7 | -31.6 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.586 | -0.079 | -0.248 | -30.5 | -85.1 |
| Financing Cash Flow Items | -5.97 | -0.781 | 0 | 116 | 215 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 49.9 | 27.8 | 0.032 | 116 | 241 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 37.2 | 9.46 | -28.9 | 78.4 | 44.7 |